Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04856189
Other study ID # UCDCC#289
Secondary ID NCI-2021-02845UC
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date April 8, 2021
Est. completion date May 1, 2024

Study information

Verified date June 2023
Source University of California, Davis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase Ib/II trial finds the best dose of selinexor and its effect with pembrolizumab in treating patients with urothelial carcinoma that are not eligible to receive the chemotherapy drug cisplatin, or have been given cisplatin and the cancer has gotten worse. Patients must also have urothelial carcinoma that has spread locally, near where it started (locally advanced), or has spread to other parts of the body (metastatic). Selinexor may stop the growth of tumor cells by blocking a protein, called XPO1, that is needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving selinexor and pembrolizumab may kill more tumor cells.


Description:

PRIMARY OBJECTIVES: I. To determine the recommended phase 2 dose (RP2D) of selinexor in combination with standard-dose pembrolizumab in patients with advanced urothelial carcinoma who are cisplatin-ineligible or platinum-refractory. (Phase Ib) II. To determine the objective response rate (ORR) of selinexor in combination with pembrolizumab in patients with advanced urothelial carcinoma who are cisplatin-ineligible or platinum-refractory. (Phase II) SECONDARY OBJECTIVES: I. To further evaluate the toxicity profile of the combination of selinexor with pembrolizumab in patients with advanced urothelial carcinoma. II. To further evaluate the efficacy of the combination of selinexor with pembrolizumab in patients with advanced urothelial carcinoma as defined by progression-free survival (PFS).


Recruitment information / eligibility

Status Recruiting
Enrollment 12
Est. completion date May 1, 2024
Est. primary completion date May 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Pathologically confirmed locally advanced or metastatic urothelial carcinoma by histology - Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 - Not eligible to receive cisplatin-based chemotherapy due to renal dysfunction (defined as creatinine clearance [CrCl] =< 60 mL/min), > grade 2 peripheral neuropathy, or ototoxicity (defined as >= grade 2 hearing loss); OR unwillingness of patient to receive cisplatin; OR progressed on one platinum-based chemotherapy regimen for advanced disease - May have had neoadjuvant or adjuvant platinum-based chemotherapy or intravesical therapy in the past - >= 18 years of age - Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2 - Life expectancy >= 3 months - Absolute neutrophil count (ANC) >= 1 × 10^9/L - Platelet count >= 75 × 10^9/L (patients for whom <50% of bone marrow nucleated cells are plasma cells) or >= 50,000/mm3 (patients for whom >= 50% of bone marrow nucleated cells are plasma cells) - Hemoglobin >= 9 g/dL (may have been transfused) - Total bilirubin level =< 1.5 x the upper limit of normal (ULN) range (except patients with Gilbert's syndrome who must have a total bilirubin of < 3 x ULN) - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 2.5 x ULN, or AST and ALT levels =< 5 x ULN (for subjects with documented metastatic disease to the liver) - Creatinine clearance >= 30 mL/min by Cockcroft-Gault formula - Subjects with active hepatitis B virus (Hep B) are allowed if antiviral therapy for hepatitis B has been given for > 8 weeks and viral load is < 100 IU/mL prior to first dose of trial treatment. Subjects with untreated hepatitis C virus (HCV) are allowed. Subjects with human immunodeficiency virus (HIV) who have CD4+ T-cell counts >= 350 cells/uL and no history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections in the last year are allowed - Willingness to undergo mandatory pre-treatment biopsy (unless there is adequate archival tumor specimen available for PD-L1 IHC evaluation) - Female subjects who are of non-reproductive potential (i.e., post-menopausal by history - no menses for >= 1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy). Or, female subjects of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the first study drug administration - Male and female subjects who are of reproductive potential must agree to use highly effective method of birth control (e.g., implants, injectables, birth control pills with two hormones, intrauterine devices [IUDs], complete abstinence or sterilized partner, and female sterilization) and a barrier method (e.g., condoms, vaginal ring, sponge, etc.) during the period of therapy and for 4 months after the last dose of study drug - Ability to understand and willingness to sign an informed consent form - Ability to adhere to the study visit schedule and other protocol requirements - Must be able to swallow study drug Exclusion Criteria: - Receiving radiation =< 14 days prior to enrollment to the site of selected target lesions - Systemic therapy for cancer =< 21 days prior to enrollment - Autoimmune disorder requiring active therapy as defined by corticosteroids at a dose >= 10 mg oral prednisone or the equivalent or requiring chronic immunosuppressive therapy - Use of corticosteroids =< 14 days prior to enrollment at a dose of >= 10 mg oral prednisone or the equivalent per day - Received immune checkpoint inhibitor therapy (anti-PD-1, anti-PD-L1, or anti-CTLA4 directed therapy) on a prior clinical trial - Has received selinexor or another XPO1 inhibitor previously - Any active gastrointestinal dysfunction that could interfere with absorption of study treatment in the opinion of the investigator - Pregnant or lactating women - Any condition that would prohibit the understanding or rendering of informed consent - Any condition including additional malignancies, laboratory abnormalities, or psychiatric illness that in the opinion of the investigator would interfere with the patient's safety or compliance while on trial - Severe infection that in the opinion of the investigator would interfere with patient safety or compliance on trial within 4 weeks prior to enrollment

Study Design


Intervention

Biological:
Pembrolizumab
Given IV
Drug:
Selinexor
Given PO

Locations

Country Name City State
United States University of California Davis Comprehensive Cancer Center Sacramento California

Sponsors (3)

Lead Sponsor Collaborator
Mamta Parikh Karyopharm Therapeutics Inc, National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Recommended phase 2 dose (RP2D) (Phase Ib) Defined by dose-limiting toxicity (DLTs). Dose limiting toxicities will be listed according to dose level. Separately by dose level and the expansion cohort (as well as for the total RP2D cohort), adverse events (AEs) will be summarized as number of patients according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 term and grade, where grade is the maximum across a patient's treatment period. Up to 2 cycles (each cycle is 21 days)
Primary Objective response rate (ORR) (Phase II) ORR, calculated as the total number of patients with a confirmed complete response or partial response, will be reported as a percentage of total evaluable patients. Response will be reported using Response Evaluation Criteria in Solid Tumor 1.1 definitions. ORR will be summarized by exact binomial 95% confidence intervals (CI). Up to 2 years
Secondary Incidence of grade 3 or higher AEs Defined by NCI CTCAE version 5. The number (%) of patients who experience >= 1 grade 3-5 AEs will be reported, as well as the proportion with exact binomial 95% CI. Up to 2 years
Secondary Progression-free survival (PFS) Assessed with Kaplan-Meier plot and estimate of median PFS with 95% CI. From enrollment to trial to time of disease progression or death from any cause, assessed up to 2 years
See also
  Status Clinical Trial Phase
Completed NCT05700344 - SOGUG-AVELUMAB_RWD
Recruiting NCT04623502 - An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy N/A
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Recruiting NCT04953104 - Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression Phase 2
Withdrawn NCT06050954 - A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA) Phase 2
Active, not recruiting NCT03534804 - Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma Phase 2
Active, not recruiting NCT00365157 - Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction Phase 1/Phase 2
Withdrawn NCT06018116 - A Canadian Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer. Phase 2
Recruiting NCT05544552 - Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations Phase 1/Phase 2
Recruiting NCT04936230 - Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer Phase 2
Active, not recruiting NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Phase 1
Terminated NCT05052372 - Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
Terminated NCT03115801 - A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers Phase 2
Active, not recruiting NCT03854474 - Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma Phase 1/Phase 2
Terminated NCT02693717 - Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer Phase 2
Recruiting NCT04848519 - Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma Phase 2
Active, not recruiting NCT04724018 - Sacituzumab Govitecan Plus EV in Metastatic UC Phase 1
Terminated NCT04003610 - Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) Phase 2
Recruiting NCT04383067 - A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients Phase 2
Not yet recruiting NCT03108261 - Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations Phase 2